Cas:65087-59-4 n-butyl-d9-benzene manufacturer & supplier

Chemical Name:n-butyl-d9-benzene

CAS.NO:65087-59-4

Synonyms:n-butyl-d9-benzene

Molecular Formula:C₁₀H₅D₉

Molecular Weight:143.27400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:183.495ºC at 760 mmHg

Density:0.923 g/cm3

Index of Refraction:

PSA:

Exact Mass:143.16600

LogP:3.02920

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like n-butyl-d9-benzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,n-butyl-d9-benzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,n-butyl-d9-benzene Use and application,n-butyl-d9-benzene technical grade,usp/ep/jp grade.

Related News: The firm also has several lawyers whose reputations would carry weight with the Justice Department and the FDA, including former Attorney General Eric Holder, legal experts said. Gerald Masoudi, the Covington partner who handled the recent inquiry for Lilly, once served as the FDA’s chief counsel. Masoudi did not respond to requests for comment. n-butyl-d9-benzene manufacturer The Company��s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). n-butyl-d9-benzene supplier The firm also has several lawyers whose reputations would carry weight with the Justice Department and the FDA, including former Attorney General Eric Holder, legal experts said. Gerald Masoudi, the Covington partner who handled the recent inquiry for Lilly, once served as the FDA’s chief counsel. Masoudi did not respond to requests for comment. n-butyl-d9-benzene vendor This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine. n-butyl-d9-benzene factory The Company��s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).